Two experimental drugs failed to prevent or slow mental decline in a study of people who are virtually destined to develop Alzheimer's disease at a relatively young age because they inherited rare gene flaws.
The results announced Monday are another disappointment for the approach that scientists have focused on for years — trying to remove a harmful protein that builds up in the brains of people with Alzheimer's, the leading cause of dementia.
A doctor looks at a PET brain scan at the Banner Alzheimer's Institute in Phoenix. VOA
"We actually don't even know yet what the drugs did" in term of removing that protein because those results are still being analyzed, said study leader Dr. Randall Bateman at Washington University in St. Louis, Missouri.
But after five years on average, the main goal of the study was not met: people on either of the drugs scored about the same on thinking and memory tests as others given placebo treatments. (VOA)
NewsGram invites you to join our exclusive Certification Program designed to help you excel in Journalism and Content Creation!
What You Get:
✅ Author Profile/Byline – Your own author page on NewsGram📝
✅ Certificate – Official recognition of your expertise 🎓
✅ Live Classes – Weekend sessions + One-on-one sessions on weekdays 🎥👨🏫
✅ Article Publication – Publish for free under expert mentorship 📰✍️
✅ Freelancing Opportunity – Potential to work with NewsGram in the future 💼🚀
📅 Limited slots available! Take the next step in your career and gain hands-on experience in digital media content writing.
Apply right now with a mail to education@newsgram.com.
For more details, see the Course Guide.